ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

Reasons NIH Women Scientists Leave: Family Roles, Lower Confidence.

November 2, 2007

Judge Invalidates Bristol-Myers’ Claims For The Administration Of Taxol.

March 3, 2000

In Brief: DOE honors radiation Therapy Pioneers; Center Honors Nixon, Lansing, Coffey

June 20, 1997

ACS Goal To Raise Percentage Of Women Who Get Mammograms

July 31, 1992

Studies On Diet Add To Information On Fiber, Fat, Meat

April 5, 1991

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014